Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
Rethinking how we manage osteoarthritis pain
Alex Page, pharmacist at Outback Pharmacies and former winner of the PSA Award for QUM in Pain Management, and Joyce McSwan, Founder and Managing...
PSA: pharmacists need support to improve Australia’s health
Following the announcement of this year’s Federal Election date, PSA looks forward to working with an incoming Government to support a healthier Australia by...
World AIDS Day – 1 December
Men who have sex with men and use the human immunodeficiency virus (HIV) prevention pill have lower anxiety, new Australian research has revealed.
Those who take...
From the President: Be ready for more vaccine speed bumps
Last month, community pharmacists in regional Queensland commenced vaccinating their communities against COVID-19.
PSA launches bold five-year plan for pharmacy
A new vision for the role of pharmacists launched PSA18 in Sydney today, with the unveiling of PSA’s Pharmacists in 2023: A Discussion Paper,...
Engaging hyper-connected patients
At PSA17, I discussed how pharmacists can engage hyper-connected patients to help them avoid misinformation or misadventure. In case you missed it, here are...
